Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Recommendation of “Buy” by Brokerages

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has been assigned a consensus recommendation of “Buy” from the eight analysts that are covering the stock, MarketBeat.com reports. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $71.40.

A number of brokerages have issued reports on ARCT. HC Wainwright reiterated a “buy” rating and set a $63.00 price target on shares of Arcturus Therapeutics in a research report on Tuesday, October 1st. Leerink Partnrs upgraded Arcturus Therapeutics to a “strong-buy” rating in a research report on Monday, August 12th. Leerink Partners initiated coverage on Arcturus Therapeutics in a research report on Monday, August 12th. They set an “outperform” rating and a $70.00 price objective on the stock. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Arcturus Therapeutics in a research note on Monday, September 9th.

Arcturus Therapeutics Stock Down 1.0 %

Arcturus Therapeutics stock opened at $17.82 on Tuesday. The firm has a market cap of $479.93 million, a price-to-earnings ratio of -6.93 and a beta of 2.64. The business’s 50-day moving average price is $20.78 and its 200 day moving average price is $24.44. Arcturus Therapeutics has a 52 week low of $17.50 and a 52 week high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.85) by $1.21. The company had revenue of $49.86 million for the quarter, compared to the consensus estimate of $21.00 million. Arcturus Therapeutics had a negative return on equity of 25.47% and a negative net margin of 41.21%. During the same quarter in the prior year, the business posted ($1.98) earnings per share. Equities analysts expect that Arcturus Therapeutics will post -2.6 EPS for the current year.

Insider Activity at Arcturus Therapeutics

In related news, COO Pad Chivukula sold 12,000 shares of Arcturus Therapeutics stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $20.76, for a total value of $249,120.00. Following the completion of the transaction, the chief operating officer now directly owns 435,334 shares in the company, valued at approximately $9,037,533.84. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 15.30% of the stock is currently owned by company insiders.

Institutional Trading of Arcturus Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Los Angeles Capital Management LLC purchased a new stake in Arcturus Therapeutics during the 3rd quarter worth about $544,000. ARK Investment Management LLC lifted its holdings in Arcturus Therapeutics by 6.9% during the 3rd quarter. ARK Investment Management LLC now owns 2,101,038 shares of the biotechnology company’s stock worth $48,765,000 after buying an additional 136,074 shares during the last quarter. Empire Life Investments Inc. purchased a new stake in Arcturus Therapeutics during the 3rd quarter worth about $3,498,000. China Universal Asset Management Co. Ltd. lifted its holdings in Arcturus Therapeutics by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company’s stock worth $121,000 after buying an additional 2,038 shares during the last quarter. Finally, nVerses Capital LLC purchased a new stake in Arcturus Therapeutics during the 3rd quarter worth about $42,000. 94.54% of the stock is owned by hedge funds and other institutional investors.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.